Evidence map›Paper›PMID 34854262›Full record

ArticleJournal of cachexia, sarcopenia and muscle2022

Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats.

Olivier Le Bacquer, Jérôme Salles, Fabiana Piscitelli, Phelipe Sanchez, Vincent Martin, Christophe Montaurier, Vincenzo Di Marzo, Stéphane Walrand

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Fatty acid amides as potential circulating biomarkers for sarcopenia.Journal of cachexia, sarcopenia and muscle · 2023
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Olivier Le BacquerINRAE, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, Clermont-Ferrand, France.ORCID 0000-0003-3805-973X
Jérôme SallesINRAE, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, Clermont-Ferrand, France.
Fabiana PiscitelliInstitute of Biomolecular Chemistry, National Research Council, Pozzuoli, Italy.
Phelipe SanchezINRAE, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, Clermont-Ferrand, France.
Vincent MartinAME2P, Université Clermont Auvergne, Clermont-Ferrand, France.
Christophe MontaurierINRAE, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, Clermont-Ferrand, France.
Vincenzo Di MarzoInstitute of Biomolecular Chemistry, National Research Council, Pozzuoli, Italy.
Stéphane WalrandINRAE, Unité de Nutrition Humaine (UNH), Université Clermont Auvergne, Clermont-Ferrand, France.
Université Clermont Auvergne · FRUniversity of Padua · ITInstitut Universitaire de France · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivation of the endocannabinoid system (ECS) is associated with the development of obesity and insulin resistance, and with perturbed skeletal muscle development. Age-related sarcopenia is a progressive and generalized skeletal muscle disorder involving an accelerated loss of muscle mass and function, with changes in skeletal muscle protein homeostasis due to lipid accumulation and anabolic resistance. Hence, both obesity and sarcopenia share a common set of pathophysiological alterations leading to skeletal muscle impairment. The aim of this study was to characterize how sarcopenia impacts the ECS and if these modifications were related to the loss of muscle mass and function associated with aging in rats.

methodsSix-month-old and 24-month-old male rats were used to measure the contractile properties of the plantarflexors (isometric torque-frequency relationship & concentric power-velocity relationship) and to evaluate locomotor activity, motor coordination, and voluntary gait by open field, rotarod, and catwalk tests, respectively. Levels of endocannabinoids (AEA & 2-AG) and endocannabinoid-like molecules (OEA & PEA) were measured by LCF-MS/MS in plasma, skeletal muscle, and adipose tissue, while the expression of genes coding for the ECS were investigated by quantitative reverse transcription PCR (RT-qPCR).

resultsSarcopenia in old rats was exemplified by a 49% decrease in hindlimb muscle mass (P < 0.01), which was associated with severe impairment of isometric torque, power, voluntary locomotor activity, motor coordination, and gait quality. Sarcopenia was associated with (1) increased 2-AG (+32%, P = 0.07) and reduced PEA and OEA levels in the plasma (-25% and -40%, respectively, P < 0.01); (2) an increased content of AEA, PEA, and OEA in subcutaneous adipose tissue (P < 0.01); and (3) a four-fold increase of 2-AG content in the soleus (P < 0.01) and a reduced OEA content in EDL (-80%, P < 0.01). These alterations were associated with profound modifications in the expression of the ECS genes in the adipose tissue and skeletal muscle.

conclusionsTaken together, these findings demonstrate that circulating and peripheral tissue endocannabinoid tone are altered in sarcopenia. They also demonstrate that OEA plasma levels are associated with skeletal muscle function and loss of locomotor activity in rats, suggesting OEA could be used as a circulating biomarker for sarcopenia.

Indexed as

Insulin ResistanceSarcopeniaAnimalsEndocannabinoidsMaleObesityRatsTandem Mass SpectrometryEndocannabinoidsEndocannabinoidsMuscle functionSarcopeniaSkeletal muscle

Identifiers

PMID34854262
PMCPMC8818601
OpenAlexW3216171698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.